Skip to main content

Table 2 Biodistribution (0.3 MBq/0.075 nmol) of 177 Lu-labelled BN analogues in nude mice bearing PC-3 tumour

From: PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with 177Lu-DOTA-bombesin analogues

  177Lu-DOTA-Lys-BN 177Lu-DOTA-PEG 5k-Lys-BN 177Lu-DOTA-Lys-BN 177Lu-DOTA-PEG 5k-Lys-BN
Tissue 1 h p.i. 24 h p.i. 1 h p.i. 24 h p.i. 1 h p.i. blocked 1 h p.i. blocked
Blood 0.24 ± 0.07 0.00 ± 0.00 1.54 ± 0.33* 0.01 ± 0.00*   
Heart 0.14 ± 0.06 0.01 ± 0.01 0.49 ± 0.05 0.04 ± 0.01   
Lung 0.36 ± 0.08 0.02 ± 0.01 1.10 ± 0.15 0.13 ± 0.02   
Spleen 0.42 ± 0.12 0.18 ± 0.04 0.72 ± 0.02 0.19 ± 0.03   
Kidneys 2.86 ± 0.63 1.41 ± 0.14 4.89 ± 1.33 1.84 ± 0.52   
Pancreas 8.68 ± 1.95 4.27 ± 0.85 9.62 ± 2.39 4.87 ± 1.11 0.49 ± 0.22** 0.98 ± 0.59*
Stomach 0.72 ± 0.19 0.10 ± 0.02 1.12 ± 0.15 0.22 ± 0.07   
Small intestine 1.38 ± 0.41 0.16 ± 0.03 1.18 ± 0.22 0.17 ± 0.12   
Colon 1.64 ± 0.40 0.36 ± 0.09 2.19 ± 0.91 0.45 ± 0.21 0.36 ± 0.07** 0.66 ± 0.14
Liver 0.26 ± 0.09 0.09 ± 0.02 0.57 ± 0.04 0.16 ± 0.09   
Muscle 0.20 ± 0.24 0.01 ± 0.00 0.31 ± 0.06 0.42 ± 0.69   
Bone 0.36 ± 0.24 0.02 ± 0.01 0.70 ± 0.06 0.58 ± 0.44   
Tumour 1.88 ± 0.47 0.54 ± 0.30 3.43 ± 0.63* 1.04 ± 0.04 0.55 ± 0.03* 1.02 ± 0.34**
  1. *P < 0.05; **P < 0.01. Data in percentage of injected dose per gram of tissue (%ID/g), expressed as mean ± SD at 1 and 24 h p.i. (n = 3 to 4).